Experimental cell therapy takes on Hard-to-Treat myeloma
NCT ID NCT04674813
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial tested a new cell therapy called CC-95266 in 130 people with multiple myeloma that had come back or stopped responding to treatment. Participants also received chemotherapy drugs to prepare their bodies for the cell infusion. The main goals were to check safety and find the right dose, while also looking at how well the treatment worked.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
CC-95266 (a cell therapy) given with chemotherapy drugs fludarabine, cyclophosphamide, and bendamustine
What this could lead to
If successful, this could point toward a new treatment option for people with multiple myeloma that has not responded to other therapies.
What could go wrong
This is an early phase 1 trial focused on safety, so it is too soon to know if the treatment works. Side effects from the cell therapy and chemotherapy may be significant.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Local Institution - 001
Nashville, Tennessee, 37203, United States
-
Local Institution - 002
Denver, Colorado, 80218, United States
-
Local Institution - 003
Seattle, Washington, 98104, United States
-
Local Institution - 005
Birmingham, Alabama, 10016, United States
-
Local Institution - 006
Dallas, Texas, 75390, United States
-
Local Institution - 008
Baltimore, Maryland, 21201, United States
-
Local Institution - 009
Duarte, California, 91010-301, United States
-
Local Institution - 010
Boston, Massachusetts, 02215, United States
-
Local Institution - 011
New York, New York, 10029, United States
-
Local Institution - 012
San Francisco, California, 94143, United States